摘要
目的探讨D2-40标记乳腺癌组织淋巴管的可行性（LVI）与淋巴结转移的关系。方法采用二步法免疫组化染色检测72例乳腺癌和15例乳腺良性病变组织中D2-40的表达及淋巴管受癌细胞浸润情况，分析其与乳腺癌腋窝淋巴结转移的关系。结果乳腺癌组织中的LVI阳性率为69．4％，腋淋巴结转移组为85．7％，未转移组为54．1％，转移组高于未转移组，差异有统计学意义（P〈0．01）；LVI与患者腋窝淋巴结转移呈ft．相关（r=0．382），淋巴结转移〉10个患者中LVI阳性率最高（100％），淋巴结阴性组LVI阳性率最低（54．1％）。结论D2-40可作为可靠的淋巴管标记物；LVI与乳腺癌淋巴结转移呈正相关，早于淋巴结转移出现，可作为临床病理学的检测项目。
Objective To investigate the feasibility of D2-d0 for the detection of lymphatic and clinicopathological of lymphatic vessel invasion in breast cancer. Methods Immunohistochemistry was used to detect the expression of D240 in 72 cases of breast cancer and 15 cases of benigh breast tumor and lymphatic invasion, and the correlation of D240 expression with axillary lymph node metastasis was analyzed. Results LVI positive rate in breast cancer was 69.4 % , it was 85.7 % in lymph node-positive group, 54. 1% in lymph node-negative group, the former was significantly higher than the latter（P 〈0.01 ） ; LVI was positively correlated with axillary lymph node metastasis（ r = 0. 382）. Conclusions D240 can specially mark the lymphatic vessel in breast cancer, get a better staining result, which makes it a reliable marker of lymph vessel; LVI is positively correlated with axillary lymph node metastasis and earlier than axillary lymph node metastasis, so it should be the conven- tional clinical pathological testing item.
出处
《中国实用医刊》
2014年第6期19-21,共3页
Chinese Journal of Practical Medicine
